drugset / Trial / NCT01659151

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

NCT01659151

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body from viral infections, help other cells fight bacterial and fungal infections, produce antibodies, fight cancers, and coordinate the activities of other cells in the immune system.

Timeline

Start
2012-08-03
Primary completion
2021-10-06
Completion
2025-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemurafenib Small molecule
Subject aldesleukin Protein / enzyme biologic
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule

Indications